SOHO Brazil 2022

https://rvmais.iweventos.com.br/site/sintoma2022

 

SOHO Brazil 2022
Avatar

SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: What Is the Most Recent in Practice and Research?

By SOHO Brazil 2022 FEATURING Daniel Pollyea, Phillip Scheinberg
By SOHO Brazil 2022 FEATURING Daniel Pollyea, Phillip Scheinberg
17 views
August 30, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

15:11
Incyte

The Importance of Intervention at the First Signs of Initial Systemi…

Feat. P. Chaudhary

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
Leukemia
23:10

SOHO Brazil 2022: All You Need to Know (Until Now) About Targeted Th…

SOHO Brazil 2022

K. Pratz, P. Scheinberg

89 views
32:48

SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indi…

SOHO Brazil 2022

M. Bishop, P. Scheinberg

15 views
16:45

SOHO Brazil 2022 on CLL: The PI3K Inhibitors, the "Not-So-New Kid on…

SOHO Brazil 2022

N. Jain, P. Scheinberg

14 views
20:09

SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-U…

SOHO Brazil 2022

N. Jain, P. Scheinberg

23 views
22:54

SOHO Brazil 2022 on Ph+ ALL: Is the Combination With TKIs Curing Pat…

SOHO Brazil 2022

J. Ribera, P. Scheinberg

48 views
20:04

SOHO Brazil 2022 on High-Risk AML: Is Conventional Chemo Still the B…

SOHO Brazil 2022

D. Pollyea, P. Scheinberg

16 views
20:23

SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: What…

SOHO Brazil 2022

D. Pollyea, P. Scheinberg

17 views
26:48

SOHO Brazil 2022 on CLL: Do BTKi + BCL2 Inhibitors Need a Partner?

SOHO Brazil 2022

N. Jain, P. Scheinberg

16 views
25:29

SOHO Brazil 2022: Can Someone Be Destined to Develop AML? Understand…

SOHO Brazil 2022

L. Godley, P. Scheinberg

34 views